Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. (Record no. 14739966)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02223 a2200565 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250514182415.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200404s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0732-183X |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1200/JCO.2004.10.046 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Tedesco, K L |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20040408 |
| 245 00 - TITLE STATEMENT | |
| Title | Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Date of publication, distribution, etc. | Mar 2004 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1071-7 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Breast Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease-Free Survival |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Docetaxel |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gene Expression Regulation, Neoplastic |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | In Situ Hybridization, Fluorescence |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptor, ErbB-2 |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptor, ErbB-3 |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Survival Analysis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Taxoids |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Trastuzumab |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | United States |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Up-Regulation |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Thor, A D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Johnson, D H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shyr, Y |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Blum, K A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Goldstein, L J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gradishar, W J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nicholson, B P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Merkel, D E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Murrey, D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Edgerton, S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sledge, G W |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Related parts | vol. 22 |
| -- | no. 6 |
| -- | p. 1071-7 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1200/JCO.2004.10.046">https://doi.org/10.1200/JCO.2004.10.046</a> |
| Public note | Available from publisher's website |
No items available.